---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000047"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:18:50.837547+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma restates 2023 financials; non-cash error adds $348M loss; going concern doubt

## Summary
- Board concludes Q3 2023 and FY 2023 financials unreliable due to IPR&D write-off misclassification.
- Non-cash correction increases reported loss by $348M; cash balances and operating cash flow unaffected.
- Company plans to file restated audited FY 2023 financials and amend Q3 2023 10-Q.
- Expects to disclose additional material weakness and substantial doubt about going concern for 12 months.
- KPMG notified; error has no impact on prior cash or operating cash flow.

## SEC filing metadata
- accession: 0001837607-24-000047
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000047/0001837607-24-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000047/aeon-20240501x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000047
- JSON: https://secwatch.observer/filing/0001837607-24-000047.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000047.txt

## Key facts
- Auditor Changes
  AEON Biopharma, Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  - Auditor: KPMG LLP
  source text: The Company's management and the Board have discussed the matters described herein with KPMG LLP, the Company's independent registered public accounting firm. The identified error had no impact on the Company’s cash balances or operating cash flows for the quarter ended September 30, 2023 nor the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000047/0001837607-24-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.